Shares shifted as Moleculin Biotech climbed 10% to $0.45 on lingering enthusiasm from July 31 interim data showing its experimental cancer drug working in patients most doctors have nearly given up on. But with a market value barely scraping $3 million and a massive new stock offering just closed, the question is whether the science can outrun the financial math.
The Drug Works Where Others Largely Fail. With 62 patients evaluable, Moleculin's blinded data showed a 24% complete remission rate and a 37% composite complete remission rate — a measure that includes partial blood-count recoveries alongside full remissions. Critically, 48% of those patients had already failed venetoclax-based treatment, yet that subgroup posted identical remission rates of 23% and 37% . That matters because published salvage remission rates for venetoclax failures are approximately 13%, with median survival of just 2.4 months . Earlier unblinded data from the first 45 patients was even stronger: the drug arms showed complete remission rates of 43% and 36% versus 12% for the control .
The Trial Still Has a Long Way to Go. Part A enrollment stands at 67 of 90 subjects, and the full pivotal study targets roughly 282 patients . The trial uses a statistical design where lack of significance at this early look is built into the plan — meaning today's numbers are encouraging but nowhere near proof of approval. The unblinded interim showed a clear numeric advantage but remains underpowered.
Fresh Cash Came With a Steep Price. On the same day as the data release, Moleculin priced a $9.3 million offering of roughly 12.4 million shares plus warrants covering another 37.1 million shares, all at $0.75 . Proceeds fund Annamycin's clinical development and working capital . But the warrant overhang — shares that can be created when warrant holders exercise their rights — could nearly triple the share count over time. The company already burns over $6 million per quarter and posts steep operating losses .
The Bottom Line for Shareholders. At $0.45, MBRX trades at 40% below its own offering price of $0.75, signaling the market still doubts whether promising early data can survive the gauntlet of a full registration trial, continuous dilution, and a cash runway that demands repeated fundraising. The science is genuinely intriguing; the capital structure is genuinely punishing.